Publications by authors named "S Wittebol"

Claim this Profile
F
Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia.
Arnon P Kater, Marinus H J van Oers, Yvette van Norden, Lina van der Straten, Julia Driessen, Shulamiet Wittebol

Haematologica· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL.
Arnon P Kater, Sabina Kersting, Yvette van Norden, Julie Dubois, Johan A Dobber, Shulamiet Wittebol

Blood Adv· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia.
Fie J Vojdeman, Sarah E M Herman, Nikolai Kirkby, Adrian Wiestner, Mars B van T' Veer, Shulamiet Wittebol

Leuk Lymphoma· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The HOVON68 CLL trial revisited: performance status and comorbidity affect survival in elderly patients with chronic lymphocytic leukemia.
Fie Juhl Vojdeman, Mars B Van't Veer, Geir E Tjønnfjord, Maija Itälä-Remes, Eva Kimby, Shulamiet Wittebol

Leuk Lymphoma· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma.
Annemiek Broijl, Marie-José Kersten, Wendimagegn Ghidey Alemayehu, Mark-David Levin, Okke de Weerdt, Shulamit Wittebol

Haematologica· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis